HIV Exposure Assessment Starts With the Fluid, Not the Fear
A spit-in-the-eye episode, a scratch during restraint, a blood splash to the conjunctiva, and a hollow-bore needlestick do not carry the same meaning at the bedside. The difference begins with a basic infectious disease rule: HIV post-exposure prophylaxis is only relevant when a potentially infectious fluid reaches a susceptible site. Mucous membrane contact sounds alarming, but saliva without visible blood is not an HIV-transmitting fluid. Broken skin can look dramatic after a scratch, yet skin injury alone does not create HIV risk unless an infectious fluid is also involved.
That separation between anxiety and transmission biology is the entire triage problem in the emergency department. The first question is not whether the event felt unpleasant. The first question is whether the exposure had the biological ingredients needed for transmission.
Spit and Scratch Usually Fall Outside the HIV PEP Pathway
Direct saliva exposure to the eye does not warrant PEP when there is no visible blood. Saliva, tears, sweat, urine, feces, vomitus, nasal secretions, and sputum are not considered infectious for HIV unless visibly bloody. The same principle applies to a scratch from fingernails or skin trauma during restraint when there is no blood or other infectious material on the nails. These events may require wound care, reassurance, documentation, and sometimes broader occupational follow-up, but they do not meet the threshold for HIV prophylaxis.
The practical consequence is important. ED staff often overestimate HIV risk when blood is absent and the route looks dramatic. HIV transmission depends on both a transmissible fluid and an entry point. If one half of the equation is missing, PEP is not indicated.
Blood to the Eye Changes the Calculation
A blood splash into the eye during line placement is a different event entirely. Blood is a potentially infectious fluid, and the conjunctiva is a susceptible mucous membrane. The average transmission risk after mucous membrane exposure is about 0.09%, a small number that still represents a real occupational exposure. Intact skin carries no recognized transmission risk, and non-intact skin carries a lower risk that remains poorly quantified.
The low absolute probability should not be mistaken for a low-stakes decision. A recognizable blood-to-mucosa exposure enters the PEP pathway because early antiretroviral suppression can interrupt the establishment of infection before systemic spread. In practice, the issue is not whether transmission is common. It is whether the exposure is plausible enough to justify immediate treatment.
Needlestick Injuries Carry the Highest Occupational Risk
A hollow-bore needle through a glove after venepuncture from a person known to have HIV is the classic occupational exposure. Percutaneous injury has the highest documented transmission risk, estimated at about 0.3%. That estimate comes from older surveillance data, but it remains the benchmark used in clinical decision-making. Occupational HIV transmission is now uncommon, yet it has not disappeared. Surveillance in the United States has identified 58 confirmed occupational infections and about 150 possible cases, with only one confirmed infection after 1999, following a laboratory needlestick involving live HIV culture.
A needlestick is the kind of event where minutes matter. Hollow-bore devices can inoculate blood directly into tissue, and a glove offers little meaningful protection once the needle has punctured it. When the exposure is substantial, the safest approach is to begin treatment first and sort out the details in parallel.
Start PEP Fast and Finish the Full Course
Current guidance supports starting PEP as soon as possible, ideally within hours and no later than 72 hours after exposure. Waiting for source testing or baseline laboratory results should not delay the first dose. After 72 hours, routine PEP is generally not recommended, although unusual or high-risk circumstances justify expert consultation.
For most adults and adolescents, preferred regimens are three-drug, integrase inhibitor-based combinations for 28 days. Bictegravir/emtricitabine/tenofovir alafenamide is one option. Dolutegravir paired with tenofovir alafenamide or tenofovir disoproxil fumarate, plus emtricitabine or lamivudine, is another. If an integrase inhibitor-based regimen is unavailable, boosted darunavir with two nucleoside reverse transcriptase inhibitors remains an alternative, and raltegravir with emtricitabine/tenofovir remains effective when needed.
Compliance matters because missed doses and delayed initiation complicate follow-up testing. The 28-day course is not an arbitrary tradition. It reflects the time needed to suppress early viral replication long enough to prevent durable infection.
Source Testing and Exposed Clinician Testing Run in Parallel
The source patient should be assessed urgently for HIV status, treatment history, and viral load when available. Source testing should proceed immediately, but it should never hold up the first PEP dose. If the source later proves HIV-negative, PEP can be stopped. Baseline testing in the exposed clinician should include HIV Ag/Ab testing, renal function, liver function, and pregnancy testing where relevant.
An undetectable source viral load complicates the discussion rather than ending it. Viral suppression lowers biological plausibility, but the sexual-transmission evidence base for U=U cannot simply be lifted into occupational inoculation. U=U is supported by large studies in sexual transmission, including HPTN 052, PARTNER, PARTNER2, and Opposites Attract, but those data do not establish that an occupational needlestick carries zero risk when the source is suppressed. In that setting, expert consultation should guide whether to continue or discontinue prophylaxis.
Renal Disease, Pregnancy, and Existing PrEP Require Regimen Adjustments
Renal impairment changes drug selection, especially when tenofovir is part of the regimen. Tenofovir disoproxil fumarate in particular may require dose adjustment or avoidance in significant renal dysfunction. Hepatic impairment also matters, because boosted protease inhibitor regimens depend on hepatic metabolism and may need caution. These are not reasons to delay therapy; they are reasons to choose the right regimen with pharmacy or HIV specialist input.
Pregnancy and breastfeeding do not justify withholding PEP. They warrant consultation at initiation, not deferral. Cobicistat-boosted regimens are not preferred in pregnancy because drug levels are reduced. For a breastfeeding clinician, counseling should address whether breastfeeding continues or is interrupted during treatment, using shared decision-making rather than automatic rules.
Existing PrEP adds another layer. If the exposed worker is already on PrEP, adherence and regimen details need review before deciding whether additional PEP is required. Drug interactions also matter in routine practice. Bictegravir and other integrase inhibitors bind polyvalent cations, so aluminum or magnesium antacids should be separated from dosing, and calcium or iron should be taken with food when coadministered. A common antacid can quietly reduce drug exposure.
Follow-up Testing Closes the Loop
Follow-up testing at 4 to 6 weeks is recommended for personnel who started PEP more than 24 hours after exposure or who missed doses. Final testing at 12 weeks includes HIV Ag/Ab plus nucleic acid testing. Routine repeat renal and hepatic monitoring is unnecessary if baseline values are normal and treatment is tolerated; repeat creatinine, AST, and ALT testing is reserved for abnormal baseline results or symptoms.
The bedside message is straightforward: spitting, scratching, splashing, and sticking are not interchangeable events. HIV risk depends on fluid type, route of entry, and speed of response. When the exposure is real, start PEP promptly and refine the rest of the assessment without delay.